Novartis Buys Selexys As Competitors Stumble In Sickle Cell

Novartis has exercised its option to acquire Selexys in a deal worth up to $665m, following data from the Phase II SUSTAIN trial of SelG1 in sickle cell disease. The move follows several recent failures in the space.